Skip to content
Companies

Myrtelle

Gene therapy for Canavan disease

Raised to date

$24.2M

of $45M offered across 2 Form D filings

Still open
$20.8M
Investors
1
Last filed
Jul 2, 2026

About

Myrtelle Inc. is a clinical-stage gene therapy company carrying the mission of developing innovative treatments for neurodegenerative diseases that primarily affect myelin and white matter in the brain. With a particular focus on Canavan disease, the company addresses critical gaps in treatment options for rare genetic disorders of the central nervous system, aiming to improve patient outcomes significantly.

Myrtelle stands out due to its advanced gene therapy approach utilizing proprietary adeno-associated virus (AAV) technology tailored to treat complex neurological disorders.

Funding

$30M round, first sold Jun 2026$16.7M sold$13.3M still openMar 20252026
Now
  • Security to be acquiredFiled Jul 2, 2026Form D
    $16.7M/ $30M
  • DebtFiled Mar 21, 2025Form D
    $7.5M/ $15M

Product

rAAV-Olig001-ASPA

Gene Therapy

rAAV-Olig001-ASPA is an investigational gene therapy specifically designed to treat Canavan disease, a severe childhood genetic disorder characterized by the degeneration of white matter in the brain.

  • Utilizes proprietary adeno-associated virus (AAV) vector technology
  • Delivers a functional copy of the ASPA gene directly to oligodendrocytes
  • Administered via intracerebroventricular injection for effective brain cell targeting

Built for

Children diagnosed with Canavan disease

People on file